April 3, 2023 – Structure-Based Drug Design of ALK inhibitors in pre-clinical models

In the OSR1185A/185A/SPAK243A/243A knockin ES cells, we still observed that endogenous KCC2A, KCC3A and KCC4 were phosphorylated at Site-1 to a similar extent as wild-type cells; however, consistent with SPAK/OSR1 predominately phosphorylating Site-2, Site-2 phosphorylation in endogenous KCC2A, KCC3A and KCC4 was abolished in knockin ES cells lacking SPAK/OSR1 activity (Physique 6, lower panel)

By moca09Posted on April 3, 2023Posted in NKCC Cotransporter

In the OSR1185A/185A/SPAK243A/243A knockin ES cells, we still observed that endogenous KCC2A, KCC3A and KCC4 were phosphorylated at Site-1 to a similar extent as wild-type cells; however, consistent with SPAK/OSR1 predominately phosphorylating Site-2, Site-2 phosphorylation in endogenous KCC2A, KCC3A and KCC4 was abolished in knockin ES cells lacking SPAK/OSR1 activity (Physique 6, lower panel). Open […]